Navigating Unprecedented Drug Shortages in the U.S.
Drug shortages in the U.S. have hit a record high this year, with the American Society of Health-System Pharmacists (ASHP) reporting 323 active shortages. This figure exceeds the previous peak of 320 in 2014, marking the highest number since the ASHP began monitoring in 2001. The shortages span all drug classes, notably affecting generic sterile injectable medications, which include vital cancer treatments and emergency drugs used in hospital settings. Additionally, there's an ongoing shortage of ADHD medications like Adderall, further complicated by manufacturing delays and regulatory quotas.
Most drugs facing shortages are older, generic injectables, which have rigorous manufacturing standards and slim profit margins. The financial returns on these drugs are often so low that it dissuades manufacturers from producing them, leading to bankruptcies among generic drug manufacturers. The situation is exacerbated for controlled substances like Adderall due to strict production quotas set by regulatory agencies, despite there being a capacity to produce significantly more.
ASHP has proposed several policy changes to address these issues and is actively engaging with federal policymakers to implement solutions that stabilize drug supply chains and prevent future shortages.
Hot Take:
For professionals in healthcare logistics and pharmaceuticals, these shortages underscore the critical need for robust supply chain strategies and agile responses to regulatory and market changes. The ongoing drug shortages not only affect patient care but also present significant challenges and opportunities for innovation in pharmaceutical logistics and supply management.
Huy Fong Foods, the makers of the popular green-capped Sriracha sauce, has halted production due to a shortage of red winter jalapeños.